口服依托泊苷治疗老年小细胞肺癌的II期研究。
A phase II study of oral etoposide in elderly patients with small cell lung cancer.
作者信息
Smit E F, Carney D N, Harford P, Sleijfer D T, Postmus P E
机构信息
Department of Pulmonary Diseases, State University Hospital Groningen, The Netherlands.
出版信息
Thorax. 1989 Aug;44(8):631-3. doi: 10.1136/thx.44.8.631.
Abstract
Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxicity. It is concluded that etoposide in this dose regimen is an effective and well tolerated treatment for elderly patients with small cell lung cancer.
摘要
35名年龄超过70岁、此前未接受过治疗的小细胞肺癌患者接受了口服依托泊苷治疗（连续5天，800mg/m²），每4周进行一次。22例患者为广泛期疾病，13例为局限期疾病。总缓解率为71%。局限期疾病患者的中位生存期为16个月（范围6 - 32个月），广泛期疾病患者为9个月（范围4 - 17个月）。有轻度血液学毒性和脱发，但无严重毒性。结论是，这种剂量方案的依托泊苷对老年小细胞肺癌患者是一种有效且耐受性良好的治疗方法。
相似文献
1
A phase II study of oral etoposide in elderly patients with small cell lung cancer.口服依托泊苷治疗老年小细胞肺癌的II期研究。
Thorax. 1989 Aug;44(8):631-3. doi: 10.1136/thx.44.8.631.
2
Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.口服依托泊苷与标准静脉多药化疗治疗小细胞肺癌的比较：一项提前终止的多中心随机试验。医学研究委员会肺癌工作组
Lancet. 1996 Aug 31;348(9027):563-6. doi: 10.1016/s0140-6736(96)02005-3.
3
Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.口服依托泊苷对复发或难治性小细胞肺癌患者的长期给药：一项II期试验。
J Clin Oncol. 1990 Oct;8(10):1613-7. doi: 10.1200/JCO.1990.8.10.1613.
4
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.一项关于拓扑替康与口服依托泊苷（拓扑异构酶I和II抑制剂）序贯给药治疗小细胞肺癌患者的I-II期研究。
Cancer. 2002 Oct 1;95(7):1511-9. doi: 10.1002/cncr.10836.
5
Phase II study of oral VP-16-213 in small cell lung cancer.口服VP-16-213治疗小细胞肺癌的II期研究。
Cancer. 1987 Dec 15;60(12):2882-5. doi: 10.1002/1097-0142(19871215)60:12<2882::aid-cncr2820601205>3.0.co;2-a.
6
The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.
Semin Oncol. 1992 Dec;19(6 Suppl 14):36-9.
7
Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
Semin Oncol. 1990 Feb;17(1 Suppl 2):32-5.
8
Single-agent oral etoposide for elderly small cell lung cancer patients.单药口服依托泊苷治疗老年小细胞肺癌患者。
Semin Oncol. 1990 Feb;17(1 Suppl 2):49-53.
9
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.广泛期小细胞肺癌中21天口服与3天静脉注射依托泊苷联合静脉注射顺铂的治疗方案依赖性：癌症与白血病B组的一项随机III期研究
J Clin Oncol. 1995 Aug;13(8):1871-9. doi: 10.1200/JCO.1995.13.8.1871.
10
Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
J Clin Oncol. 1992 Feb;10(2):292-6. doi: 10.1200/JCO.1992.10.2.292.
引用本文的文献
1
Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy.依托泊苷纳米颗粒递送的毒理基因组学：对视网膜母细胞瘤治疗中纳米技术的潜在影响
Cancer Nanotechnol. 2011;2(1-6):21-36. doi: 10.1007/s12645-010-0010-4. Epub 2010 Dec 17.
2
Chemotherapy versus best supportive care for extensive small cell lung cancer.广泛期小细胞肺癌的化疗与最佳支持治疗对比
Cochrane Database Syst Rev. 2013 Nov 27;2013(11):CD001990. doi: 10.1002/14651858.CD001990.pub3.
3
How do patient and hospital features influence outcomes in small-cell lung cancer in England?患者和医院特征如何影响英国小细胞肺癌的结局？
Br J Cancer. 2011 Sep 6;105(6):746-52. doi: 10.1038/bjc.2011.310. Epub 2011 Aug 9.
4
Tuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino mice.吞噬细胞调理素增强了脂质体依托泊苷对瑞士白化小鼠纤维肉瘤的抗肿瘤疗效。
Mol Med. 2007 May-Jun;13(5-6):266-76. doi: 10.2119/2007–00018.Khan.
5
Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer.老年（年龄≥70岁）小细胞肺癌患者治疗中的时间和化疗治疗趋势。
Br J Cancer. 2006 Jan 16;94(1):18-21. doi: 10.1038/sj.bjc.6602888.
6
Lung cancer in the elderly: current and future chemotherapeutic options.
Drugs Aging. 2002;19(5):365-75. doi: 10.2165/00002512-200219050-00005.
7
Treatment and outcomes for elderly patients with small cell lung cancer.老年小细胞肺癌患者的治疗与预后
Drugs Aging. 2000 Sep;17(3):229-47. doi: 10.2165/00002512-200017030-00006.
8
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.卡铂联合口服依托泊苷治疗老年小细胞肺癌的II期试验
Br J Cancer. 1998 Jun;77(11):1961-5. doi: 10.1038/bjc.1998.325.
9
Age and the treatment of lung cancer.年龄与肺癌的治疗
Thorax. 1996 Jun;51(6):564-8. doi: 10.1136/thx.51.6.564.
10
The aged patient with lung cancer. Management recommendations.
Drugs Aging. 1994 Jan;4(1):34-46. doi: 10.2165/00002512-199404010-00004.
本文引用的文献
1
Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer.
Cancer Chemother Pharmacol. 1984;13(2):106-8. doi: 10.1007/BF00257124.
2
Current status of therapy for small cell carcinoma of the lung.
Cancer. 1984 Dec 1;54(11 Suppl):2722-8. doi: 10.1002/1097-0142(19841201)54:2+<2722::aid-cncr2820541419>3.0.co;2-p.
3
Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.依托泊苷口服制剂的生物利用度、药代动力学及临床效果
Cancer Treat Rep. 1985 Mar;69(3):269-73.
4
Choice of cancer therapy varies with age of patient.癌症治疗方法的选择因患者年龄而异。
JAMA. 1986 Jun 27;255(24):3385-90.
5
Lung carcinoma in the elderly population. Influence of histology on the inverse relationship of stage to age.老年人群中的肺癌。组织学对分期与年龄反比关系的影响。
Cancer. 1987 Sep 15;60(6):1331-6. doi: 10.1002/1097-0142(19870915)60:6<1331::aid-cncr2820600628>3.0.co;2-x.
6
Small cell carcinoma of the lung: influence of age on treatment outcome.
Cancer Treat Rep. 1987 Mar;71(3):291-6.
7
Vincristine and etoposide: an effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer.长春新碱与依托泊苷：一种用于广泛期小细胞肺癌且毒性降低的有效化疗方案。
Eur J Cancer Clin Oncol. 1987 Jun;23(6):619-21. doi: 10.1016/0277-5379(87)90256-2.
Zotero 插件